83 results
SC 13E3/A
EX-99
STSA
Satsuma Pharmaceuticals Inc
8 Jun 23
Going private transaction (amended)
9:16am
Benefits of Agreement
Governing Law
Exclusive Jurisdiction
Waiver of Jury Trial
Legal Holidays
Severability
Expiration
Construction
Confidentiality
Further … registered in the CVR Register will be the valid obligations of Parent, evidencing the same right and will entitle the transferee to the same benefits
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
18 May 23
January 2024 PDUFA date expected
4:20pm
), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
title, salary, duties, benefits, etc.
Purchase Order No. 0003
Pursuant to the Purchase Order No. 0003, Parent supplied 5 products i.e., (i) Fit … ) terminate the Company ESPP prior to the Effective Time.
Executive Officer Change in Control Severance Benefits
The Company has entered into Change
10-K/A
k20k h4tjf
28 Apr 23
Annual report (amended)
4:08pm
8-K
EX-10.1
rzrm7
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-2.2
290q0bh0xfh
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-99.1
7pd g98td
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-2.1
qz5v472e575peg4m0b8
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-99.1
eciizv8bxw76ne4c
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.2
pc4 4koxlsjw5t
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
36lj8lqjzm bt
30 Nov 22
Other Events
4:00pm
8-K
EX-99.1
hkgb9bzes zhj101
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
8-K
EX-1.1
n6lib u00o0
3 Nov 22
Entry into a Material Definitive Agreement
4:45pm
424B5
belrfn46y
3 Nov 22
Prospectus supplement for primary offering
4:42pm
8-K
EX-99.1
nev3ihs atbf
3 Nov 22
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:00pm
8-K
EX-99.1
2yf4m82j jv
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm